![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: INTS6 |
Gene summary for INTS6 |
![]() |
Gene information | Species | Human | Gene symbol | INTS6 | Gene ID | 26512 |
Gene name | integrator complex subunit 6 | |
Gene Alias | DBI-1 | |
Cytomap | 13q14.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UL03 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26512 | INTS6 | PTCwithHT_8 | Human | Thyroid | HT | 2.83e-04 | -3.58e-01 | 0.0351 |
26512 | INTS6 | PTCwithoutHT_2 | Human | Thyroid | PTC | 2.73e-03 | -3.50e-01 | 0.0419 |
26512 | INTS6 | male-WTA | Human | Thyroid | PTC | 1.47e-23 | -1.56e-01 | 0.1037 |
26512 | INTS6 | PTC01 | Human | Thyroid | PTC | 8.93e-10 | 4.08e-01 | 0.1899 |
26512 | INTS6 | PTC03 | Human | Thyroid | PTC | 4.70e-04 | 6.39e-01 | 0.1784 |
26512 | INTS6 | PTC04 | Human | Thyroid | PTC | 7.70e-24 | 5.64e-01 | 0.1927 |
26512 | INTS6 | PTC05 | Human | Thyroid | PTC | 1.81e-08 | 6.93e-01 | 0.2065 |
26512 | INTS6 | PTC06 | Human | Thyroid | PTC | 2.12e-21 | 1.03e+00 | 0.2057 |
26512 | INTS6 | PTC07 | Human | Thyroid | PTC | 1.52e-26 | 7.75e-01 | 0.2044 |
26512 | INTS6 | ATC09 | Human | Thyroid | ATC | 3.40e-04 | -2.16e-02 | 0.2871 |
26512 | INTS6 | ATC11 | Human | Thyroid | ATC | 2.43e-04 | 2.53e-01 | 0.3386 |
26512 | INTS6 | ATC12 | Human | Thyroid | ATC | 1.53e-16 | -2.19e-01 | 0.34 |
26512 | INTS6 | ATC13 | Human | Thyroid | ATC | 2.62e-34 | 7.75e-01 | 0.34 |
26512 | INTS6 | ATC1 | Human | Thyroid | ATC | 4.74e-02 | 3.32e-02 | 0.2878 |
26512 | INTS6 | ATC3 | Human | Thyroid | ATC | 7.88e-04 | 3.13e-01 | 0.338 |
26512 | INTS6 | ATC4 | Human | Thyroid | ATC | 6.26e-18 | -1.79e-01 | 0.34 |
26512 | INTS6 | ATC5 | Human | Thyroid | ATC | 1.73e-41 | 8.44e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344707 | Endometrium | AEH | ncRNA processing | 62/2100 | 395/18723 | 3.93e-03 | 2.65e-02 | 62 |
GO:003447012 | Endometrium | EEC | ncRNA processing | 63/2168 | 395/18723 | 5.20e-03 | 3.26e-02 | 63 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:00344704 | Liver | NAFLD | ncRNA processing | 57/1882 | 395/18723 | 3.34e-03 | 2.93e-02 | 57 |
GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
GO:0031123 | Liver | Cirrhotic | RNA 3'-end processing | 42/4634 | 116/18723 | 3.85e-03 | 2.10e-02 | 42 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:00344703 | Liver | Cyst | ncRNA processing | 25/496 | 395/18723 | 5.78e-05 | 3.01e-03 | 25 |
GO:00346602 | Liver | Cyst | ncRNA metabolic process | 28/496 | 485/18723 | 1.05e-04 | 4.67e-03 | 28 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:003112311 | Oral cavity | LP | RNA 3'-end processing | 48/4623 | 116/18723 | 5.51e-05 | 7.58e-04 | 48 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INTS6 | SNV | Missense_Mutation | novel | c.1481N>T | p.Ser494Leu | p.S494L | Q9UL03 | protein_coding | deleterious(0.01) | probably_damaging(0.947) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
INTS6 | SNV | Missense_Mutation | c.164N>C | p.Phe55Ser | p.F55S | Q9UL03 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
INTS6 | SNV | Missense_Mutation | c.2059N>G | p.Thr687Ala | p.T687A | Q9UL03 | protein_coding | tolerated(0.53) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
INTS6 | SNV | Missense_Mutation | c.1237N>C | p.Glu413Gln | p.E413Q | Q9UL03 | protein_coding | tolerated(0.27) | possibly_damaging(0.809) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
INTS6 | SNV | Missense_Mutation | novel | c.1153N>G | p.Asn385Asp | p.N385D | Q9UL03 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INTS6 | SNV | Missense_Mutation | c.520N>T | p.Arg174Trp | p.R174W | Q9UL03 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
INTS6 | SNV | Missense_Mutation | c.1904T>G | p.Val635Gly | p.V635G | Q9UL03 | protein_coding | deleterious(0.01) | possibly_damaging(0.843) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
INTS6 | SNV | Missense_Mutation | c.902N>A | p.Arg301His | p.R301H | Q9UL03 | protein_coding | deleterious(0.01) | benign(0.433) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
INTS6 | SNV | Missense_Mutation | c.1653T>A | p.Asn551Lys | p.N551K | Q9UL03 | protein_coding | tolerated(0.57) | benign(0.206) | TCGA-E2-A1IO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
INTS6 | SNV | Missense_Mutation | c.1903N>C | p.Val635Leu | p.V635L | Q9UL03 | protein_coding | tolerated(0.11) | benign(0.056) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |